Association of Circulating Ceramides With Cardiac Structure and Function in the Community: The Framingham Heart Study
Chike C Nwabuo1, Meredith Duncan2,3, Vanessa Xanthakis4,5,6
1Ronin Institute Montclair NJ.
Insights
A higher plasma ceramide ratio (C16:0/C24:0) is linked to adverse cardiac remodeling, including reduced heart function and enlarged atria. This finding may help explain the association between ceramides and heart failure risk.
Area of Science:
- Cardiovascular Medicine
- Metabolomics
- Cardiac Physiology
Background:
- Elevated plasma ceramide ratio (C16:0/C24:0) is a known risk factor for heart failure.
- The underlying mechanisms linking ceramides to heart failure, particularly cardiac remodeling, remain unclear.
Purpose of the Study:
- To investigate the association between plasma ceramide ratio (C16:0/C24:0) and cardiac remodeling.
- To explore potential pathobiological mechanisms underlying the link between ceramides and heart failure risk.
Main Methods:
- Cross-sectional study of 2652 participants from the Framingham Offspring Study.
- Assessed plasma ceramide concentrations using liquid chromatography-tandem mass spectrometry.
- Evaluated cardiac remodeling using echocardiography, including left ventricular mass, ejection fraction, atrial function, and myocardial strain.
Main Results:
- Higher C16:0/C24:0 ratio was associated with lower left ventricular ejection fraction and worse global circumferential strain.
- An elevated ceramide ratio correlated with increased left atrial end-systolic volume and reduced left atrial emptying fraction.
- No significant association was found between the ceramide ratio and E/e' or global longitudinal strain.
Conclusions:
- Findings suggest a detrimental impact of higher plasma ceramide ratio (C16:0/C24:0) on cardiac remodeling in a community sample.
- These remodeling changes may partially explain the observed association between ceramides and clinical heart failure.
Abstract:
Background A higher circulating plasma ceramide ratio (C16:0/C24:0) is associated with an increased risk of heart failure, even after accounting for standard risk factors including lipid markers. However, the pathobiological mechanisms that underlie this association are incompletely understood. We tested the hypothesis that plasma ceramide ratio (C16:0/C24:0) is associated with adverse cardiac remodeling in the community. Methods and Results We evaluated 2652 Framingham Offspring Study participants (mean age, 66±9 years; 55% women) who attended their eighth examination cycle and underwent routine echocardiography and liquid chromatography-tandem mass spectrometry-based assays for circulating ceramide concentrations. We used multivariable linear regression models to relate C16:0/C24:0 (independent variable) to the following echocardiographic measures (dependent variables; separate models for each): left ventricular mass, left ventricular ejection fraction, left atrial emptying fraction, left atrial end-systolic volume, E/e' (a measure of left ventricular diastolic function), and left ventricular global circumferential and longitudinal strain by speckle-tracking echocardiography. In multivariable-adjusted analyses, higher C16:0/C24:0 per standard deviation increment was associated with lower left ventricular ejection fraction (0.991-fold change in left ventricular ejection fraction; P=0.0004), worse global circumferential strain (β=0.34, P=0.004), higher left atrial end-systolic volume (β=2.48, p<0.0001), and lower left atrial emptying fraction (0.99-fold change; P<0.0001). The C16:0/C24:0 ratio was not associated with either E/e' or global longitudinal strain, and the association with higher left ventricular mass was rendered statistically nonsignificant upon correction for multiple comparisons. Conclusions Our cross-sectional observations in a large community-based sample are consistent with a potential detrimental impact of higher ceramide ratio (C16:0/24:0) on cardiac remodeling traits, which may partly explain the associations of these molecular species with clinical heart failure.
More Related Videos
12:15Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
Published on: February 8, 2022
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
